September 1, 2011
To Whom It May Concern,

Company Name: Taisho Pharmaceutical Co., Ltd.
Head Office: 3-24-1, Takada, Toshima-ku, Tokyo
Representative: Akira Uehara,
Chairman and CEO
(First Section of TSE: Code 4535)
Contact: Masaki Tsuboi, General Manager,
Public Relations Section
(Tel: +81-3-3985-1115)

Notice of Approval of Listing the Shares of Taisho Pharmaceutical Holdings Co., Ltd.
on the Tokyo Stock Exchange

Taisho Pharmaceutical Co., Ltd. (“Taisho”) hereby announces as set forth below that Tokyo Stock Exchange has approved today to list the shares of Taisho Pharmaceutical Holdings Co., Ltd. (“Holding Company”), which will be newly incorporated through a sole-share transfer (the “Share Transfer”) as of October 3, 2011, on the Tokyo Stock Exchange.
The shares of Taisho will be de-listed as of September 28, 2011 in accordance with the Share Transfer. The shares of Holding Company will be listed on the Tokyo Stock Exchange as of October 3, 2011.

1. Listing Schedule
- Wednesday September 28, 2011 De-listing date for Taisho
^ Monday October 3, 2011 Registration date for the incorporation of the Holding Company (effective date of the Share Transfer)
Listing date for the Holding Company’s shares

2. Exchange for Listed Securities of Holding Company
First Section of the Tokyo Stock Exchange (Code: 4581)

For details concerning to the Share Transfer, please refer to the statement “Notice of Incorporation of Holding Company through Sole-Share Transfer” released on May 13, 2011.